Abstract: Provided are a process for producing 6-methyl-3-hepten-2-one by cross aldol condensation carried out while each continuously adding to acetone, isovaleraldehyde and an aqueous alkali containing an alkaline substance; a process for producing a 6-methyl-2-heptanone analogue represented by Formula (1): wherein n is an integer of 0 or 1 or more; which comprises allowing hydrogen, acetone and an aldehyde represented by Formula (2): wherein n is as defined above; X and Y each represents a hydrogen atom or they are coupled together to form a carbon-carbon bond; and Z and W each represents a hydrogen atom or they are coupled together to form a carbon-carbon bond; to react in the presence of an aqueous alkali containing an alkaline substance, and a hydrogenation catalyst; and a process for producing phytone or isophytol using the 6-methyl-3-hepten-2-one or the 6-methyl-2-heptanone analogue.

Abstract: Provided are a process for producing 6-methyl-3-hepten-2-one by cross aldol condensation carried out while each continuously adding to acetone, isovaleraldehyde and an aqueous alkali containing an alkaline substance; a process for producing a 6-methyl-2-heptanone analogue represented by Formula (1): ##STR1## wherein n is an integer of 0 or 1 or more; which comprises allowing hydrogen, acetone and an aldehyde represented by Formula (2): ##STR2## wherein n is as defined above; X and Y each represents a hydrogen atom or they are coupled together to form a carbon-carbon bond; and Z and W each represents a hydrogen atom or they are coupled together to form a carbon-carbon bond;to react in the presence of an aqueous alkali containing an alkaline substance, and a hydrogenation catalyst; and a process for producing phyton or isophytol using the 6-methyl -3-hepten-2-one or the 6-methyl-2-heptanone analogue.

Abstract: In order to make it possible to produce 6-methylheptan-2-one, which is useful as a material for synthesizing isophytol or as a material for synthesizing fragrances such as tetrahydrolinalool and dihydrogeraniol, efficiently and in an industrially simple manner, isovaleral and acetone are subjected to aldol condensation in the presence of a basic substance to form a condensate which contains 4-hydroxy-6-methylheptan-2-one, and then the condensate is subjected to hydrogenation reaction under a dehydration condition to obtain the 6-methylheptan-2-one.

Abstract: A compound that can be converted, at a low cost and in a simple way, into 2-aryl-1,3-propanediols serving as precursors for synthesizing felbamate acting as an antiepileptic has a structure represented by Formula (1): ##STR1## wherein Ar represents an aryl group; R.sup.1 represents a hydrogen atom or is R.sup.4 or R.sup.5, where R.sup.4 represents an alkoxy group having 1 to 10 carbon atoms and R.sup.5 represents a hydroxy group or an acyloxy group having 1 to 10 carbon atoms; and R.sup.2 and R.sup.3 are hydrogen atoms at the same time or R.sup.2 and R.sup.3 together form a group represented by Formula (2): ##STR2## wherein R.sup.6 and R.sup.7 each independently represent a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, or R.sup.6 and R.sup.7 together form an oligomethylene group having 2 to 10 carbon atoms.

Abstract: The present invention provides conjugated .gamma.-hydroxybutenolide compounds represented by the general formula: ##STR1## wherein R represents, when n is 1, furyl groups, thienyl groups or naphthyl groups, unsubstituted or substituted with alkyl group or alkoxy group; phenyl groups substituted with dialkylamino group, acyl group or pyridinyl group; or ##STR2## when n is 2 or 3, phenyl groups unsubstituted or substituted with alkyl group or alkoxy group; and antiulcer agents comprising an aforementioned conjugated .gamma.-hydroxybutenolide compound as an active ingredient.

Abstract: A novel and useful method for treating and/or preventing ulcer in human beings is provided which comprises administering an effective amount of a pharmaceutical composition comprising at least one of the conjugated .gamma.-oxybutenolide compounds represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are the same or different and represent hydrogen atoms, alkyl groups, hydroxyl groups, alkoxy groups, nitro groups, cyano groups or halogen atoms; and optionally at least one pharmaceutically acceptable carrier.